Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions

Journal of Medicinal Chemistry

Volumn 59, Issue 3, 2016, Pages 788-809

  Donegan, Rebecca K ^a   Lieberman, Raquel L ^a  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; ANTIGLAUCOMA AGENT; CARBONATE DEHYDRATASE INHIBITOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; COLLAGEN TYPE 1; GELATINASE A; GELATINASE B; GLUCOSE REGULATED PROTEIN 78; INTERSTITIAL COLLAGENASE; MYOCILIN; NERVE GROWTH FACTOR; PROSTAGLANDIN DERIVATIVE; RHO KINASE INHIBITOR; ADRENERGIC RECEPTOR BLOCKING AGENT; ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; LIGAND; PROTEIN KINASE INHIBITOR; RHO KINASE;

AQUEOUS HUMOR; CELL PHAGOCYTOSIS; CLINICAL TRIAL (TOPIC); DRUG MECHANISM; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MOLECULAR THERAPY; NONHUMAN; OPHTHALMOLOGICAL IMPLANT; OPTIC NERVE LESION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN PHOSPHORYLATION; RETINA DEGENERATION; REVIEW; TONOMETRY; TRABECULECTOMY; VISUAL IMPAIRMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DEVELOPMENT; METABOLISM;

ADRENERGIC AGONISTS; ADRENERGIC ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; DRUG DISCOVERY; GLAUCOMA; HUMANS; LIGANDS; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES; SYMPATHOMIMETICS;

EID: 84958214730     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00828     Document Type: Review

References (290)

1. Alward, W. L. M. Medical management of glaucoma N. Engl. J. Med. 1998, 339, 1298-1307 10.1056/NEJM199810293391808
2. Casson, R. J.; Chidlow, G.; Wood, J. P. M.; Crowston, J. G.; Goldberg, I. Definition of glaucoma: clinical and experimental concepts Clin. Experiment. Ophthalmol. 2012, 40, 341-349 10.1111/j.1442-9071.2012.02773.x
3. Quigley, H. A.; Broman, A. T. The number of people with glaucoma worldwide in 2010 and 2020 Br. J. Ophthalmol. 2006, 90, 262-267 10.1136/bjo.2005.081224
4. Kwon, Y. H.; Fingert, J. H.; Kuehn, M. H.; Alward, W. L. Primary open-angle glaucoma N. Engl. J. Med. 2009, 360, 1113-1124 10.1056/NEJMra0804630
5. Schlötzer-Schrehardt, U. Genetics and genomics of pseudoexfoliation syndrome/glaucoma Middle East Afr. J. Ophthalmol. 2011, 18, 30-36 10.4103/0974-9233.75882
6. Kersey, J. P.; Broadway, D. C. Corticosteroid-induced glaucoma: a review of the literature Eye 2006, 20, 407-416 10.1038/sj.eye.6701895
7. Vrabec, J. P.; Levin, L. A. The neurobiology of cell death in glaucoma Eye 2007, 21, S11-S14 10.1038/sj.eye.6702880
8. Foster, P. J.; Buhrmann, R.; Quigley, H. A.; Johnson, G. J. The definition and classification of glaucoma in prevalence surveys Br. J. Ophthalmol. 2002, 86, 238-242 10.1136/bjo.86.2.238
9. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma Am. J. Ophthalmol. 1998, 126, 498-505 10.1016/S0002-9394(98)00272-4
10. Schwartz, K.; Budenz, D. Current management of glaucoma Curr. Opin. Ophthalmol. 2004, 15, 119-126 10.1097/00055735-200404000-00011
11. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures Am. J. Ophthalmol. 1998, 126, 487-497 10.1016/S0002-9394(98)00223-2
12. Agis Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration Am. J. Ophthalmol. 2000, 130, 429-440 10.1016/S0002-9394(00)00538-9
13. Stone, E. M.; Fingert, J. H.; Alward, W. L.; Nguyen, T. D.; Polansky, J. R.; Sunden, S. L.; Nishimura, D.; Clark, A. F.; Nystuen, A.; Nichols, B. E.; Mackey, D. A.; Ritch, R.; Kalenak, J. W.; Craven, E. R.; Sheffield, V. C. Identification of a gene that causes primary open angle glaucoma Science 1997, 275, 668-670 10.1126/science.275.5300.668
14. Polansky, J.; Fauss, D.; Chen, P.; Chen, H.; Lütjen-Drecoll, E.; Johnson, D.; Kurtz, R.; Ma, Z.-D.; Bloom, E.; Nguyen, T. Cellular pharmacology and molecular biology of the trabecular meshwork inducible glucocorticoid response gene product Ophthalmologica 1997, 211, 126-139 10.1159/000310780
15. Fan, B. J.; Wang, D. Y.; Lam, D. S. C.; Pang, C. P. Gene mapping for primary open angle glaucoma Clin. Biochem. 2006, 39, 249-258 10.1016/j.clinbiochem.2005.11.001
16. Allingham, R.; Liu, Y.; Rhee, D. J. The genetics of primary open-angle glaucoma: a review Exp. Eye Res. 2009, 88, 837-844 10.1016/j.exer.2008.11.003
17. Aung, T.; Rezaie, T.; Okada, K.; Viswanathan, A. C.; Child, A. H.; Brice, G.; Bhattacharya, S. S.; Lehmann, O. J.; Sarfarazi, M.; Hitchings, R. A. Clinical features and course of patients with glaucoma with the E50K mutation in the optineurin gene Invest. Ophthalmol. Visual Sci. 2005, 46, 2816-2822 10.1167/iovs.04-1133
18. Rezaie, T.; Child, A.; Hitchings, R.; Brice, G.; Miller, L.; Coca-Prados, M.; Héon, E.; Krupin, T.; Ritch, R.; Kreutzer, D. Adult-onset primary open-angle glaucoma caused by mutations in optineurin Science 2002, 295, 1077-1079 10.1126/science.1066901
19. Wolfs, R. C.; Klaver, C. C.; Ramrattan, R. S.; van Duijn, C. M.; Hofman, A.; de Jong, P. T. Genetic risk of primary open-angle glaucoma: population-based familial aggregation study Arch. Ophthalmol. 1998, 116, 1640-1645 10.1001/archopht.116.12.1640
20. Wiggs, J. L.; Hauser, M. A.; Abdrabou, W.; Allingham, R. R.; Budenz, D. L.; DelBono, E.; Friedman, D. S.; Kang, J. H.; Gaasterland, D.; Gaasterland, T. The NEIGHBOR consortium primary open-angle glaucoma genome-wide association study: rationale, study design, and clinical variables J. Glaucoma 2013, 22, 517-525 10.1097/IJG.0b013e31824d4fd8
21. Thorleifsson, G.; Walters, G. B.; Hewitt, A. W.; Masson, G.; Helgason, A.; DeWan, A.; Sigurdsson, A.; Jonasdottir, A.; Gudjonsson, S. A.; Magnusson, K. P. Common variants near CAV1 and CAV2 are associated with primary open-angle glaucoma Nat. Genet. 2010, 42, 906-909 10.1038/ng.661
22. Wiggs, J. L.; Kang, J. H.; Yaspan, B. L.; Mirel, D. B.; Laurie, C.; Crenshaw, A.; Brodeur, W.; Gogarten, S.; Olson, L. M.; Abdrabou, W. Common variants near CAV1 and CAV2 are associated with primary open-angle glaucoma in caucasians from the United States Hum. Mol. Genet. 2011, 20, 4707-4713 10.1093/hmg/ddr382
23. Vasiliou, V.; Gonzalez, F. J. Role of CYP1B1 in glaucoma Annu. Rev. Pharmacol. Toxicol. 2008, 48, 333-358 10.1146/annurev.pharmtox.48.061807.154729
24. Goel, M.; Picciani, R. G.; Lee, R. K.; Bhattacharya, S. K. Aqueous humor dynamics: a review Open Ophthalmol. J. 2010, 4, 52-59 10.2174/1874364101004010052
25. Do, C.; Civan, M. Basis of chloride transport in ciliary epithelium J. Membr. Biol. 2004, 200, 1-13 10.1007/s00232-004-0688-5
26. Chen, S.; Inoue, R.; Inomata, H.; Ito, Y. Role of cyclic AMP-induced Cl conductance in aqueous humour formation by the dog ciliary epithelium Br. J. Pharmacol. 1994, 112, 1137-1145 10.1111/j.1476-5381.1994.tb13202.x
27. Do, C.-W.; Kong, C.-W.; To, C.-H. cAMP inhibits transepithelial chloride secretion across bovine ciliary body/epithelium Invest. Ophthalmol. Visual Sci. 2004, 45, 3638-3643 10.1167/iovs.03-1343
28. Gabelt, B. A. T.; Kaufman, P. L. Changes in aqueous humor dynamics with age and glaucoma Prog. Retinal Eye Res. 2005, 24, 612-637 10.1016/j.preteyeres.2004.10.003
29. Toris, C. B.; Yablonski, M. E.; Wang, Y.-L.; Camras, C. B. Aqueous humor dynamics in the aging human eye Am. J. Ophthalmol. 1999, 127, 407-412 10.1016/S0002-9394(98)00436-X
30. Last, J. A.; Pan, T.; Ding, Y.; Reilly, C. M.; Keller, K.; Acott, T. S.; Fautsch, M. P.; Murphy, C. J.; Russell, P. Elastic modulus determination of normal and glaucomatous human trabecular meshwork Invest. Ophthalmol. Visual Sci. 2011, 52, 2147-2152 10.1167/iovs.10-6342
31. Stamer, W. D.; Braakman, S. T.; Zhou, E. H.; Ethier, C. R.; Fredberg, J. J.; Overby, D. R.; Johnson, M. Biomechanics of Schlemm's canal endothelium and intraocular pressure reduction Prog. Retinal Eye Res. 2015, 44, 86-98 10.1016/j.preteyeres.2014.08.002
32. Tektas, O. Y.; Lutjen-Drecoll, E. Structural changes of the trabecular meshwork in different kinds of glaucoma Exp. Eye Res. 2009, 88, 769-775 10.1016/j.exer.2008.11.025
33. Grossniklaus, H. E.; Nickerson, J. M.; Edelhauser, H. F.; Bergman, L. A.; Berglin, L. Anatomic alterations in aging and age-related diseases of the eye Invest. Ophthalmol. Visual Sci. 2013, 54, ORSF23-ORSF27 10.1167/iovs.13-12711
34. Weinreb, R. N.; Lindsey, J. D. The importance of models in glaucoma research J. Glaucoma 2005, 14, 302-304 10.1097/01.ijg.0000169395.47921.02
35. McNally, S.; O'Brien, C. J. Drug discovery in glaucoma and the role of animal models Drug Discovery Today: Dis. Models 2013, 10, e207-e214 10.1016/j.ddmod.2013.12.002
36. Bouhenni, R. A.; Dunmire, J.; Sewell, A.; Edward, D. P. Animal models of glaucoma J. Biomed. Biotechnol. 2012, 2012, 692609 10.1155/2012/692609
37. Kontiola, A. A new electromechanical method for measuring intraocular pressure Doc. Ophthalmol. 1997, 93, 265-276 10.1007/BF02569066
38. Martinez-de-la-Casa, J. M.; Garcia-Feijoo, J.; Castillo, A.; Garcia-Sanchez, J. Reproducibility and clinical evaluation of rebound tonometry Invest. Ophthalmol. Visual Sci. 2005, 46, 4578-4580 10.1167/iovs.05-0586
39. Cervino, A. Rebound tonometry: new opportunities and limitations of non-invasive determination of intraocular pressure Br. J. Ophthalmol. 2006, 90, 1444-1446 10.1136/bjo.2006.102970
40. Hann, C. R.; Vercnocke, A. J.; Bentley, M. D.; Jorgensen, S. M.; Fautsch, M. P. Anatomic changes in Schlemm's canal and collector channels in normal and primary open-angle glaucoma eyes using low and high perfusion pressures Invest. Ophthalmol. Visual Sci. 2014, 55, 5834-5841 10.1167/iovs.14-14128
41. Weinreb, R. N.; Khaw, P. T. Primary open-angle glaucoma Lancet 2004, 363, 1711-1720 10.1016/S0140-6736(04)16257-0
42. Bucolo, C.; Salomone, S.; Drago, F.; Reibaldi, M.; Longo, A.; Uva, M. G. Pharmacological management of ocular hypertension: current approaches and future prospective Curr. Opin. Pharmacol. 2013, 13, 50-55 10.1016/j.coph.2012.09.012
43. Beidoe, G.; Mousa, S. A. Current primary open-angle glaucoma treatments and future directions Clin. Ophthalmol. 2012, 6, 1699-1707 10.2147/OPTH.S32933
44. Bagnis, A.; Papadia, M.; Scotto, R.; Traverso, C. E. Current and emerging medical therapies in the treatment of glaucoma Expert Opin. Emerging Drugs 2011, 16, 293-307 10.1517/14728214.2011.563733
45. Weinreb, R. N.; Aung, T.; Medeiros, F. A. The pathophysiology and treatment of glaucoma: a review JAMA 2014, 311, 1901-1911 10.1001/jama.2014.3192
46. Realini, T. A history of glaucoma pharmacology Optom. Vis. Sci. 2011, 88, 36-38 10.1097/OPX.0b013e3182058ead
47. Wiederholt, M.; Schäfer, R.; Wagner, U.; Lepple-Wienhues, A. Contractile response of the isolated trabecular meshwork and ciliary muscle to cholinergic and adrenergic agents Ger. J. Ophthalmol. 1996, 5, 146-153
48. Hoyng, P. J.; van Beek, L. Pharmacological therapy for glaucoma Drugs 2000, 59, 411-434 10.2165/00003495-200059030-00003
49. Arthur, S.; Cantor, L. B. Update on the role of alpha-agonists in glaucoma management Exp. Eye Res. 2011, 93, 271-283 10.1016/j.exer.2011.04.002
50. Remaury, A.; Larrouy, D.; Daviaud, D.; Rouot, B.; Paris, H. Coupling of the alpha 2-adrenergic receptor to the inhibitory G-protein Gi and adenylate cyclase in HT29 cells Biochem. J. 1993, 292, 283-288 10.1042/bj2920283
51. Lim, J. J.; Liu, Y.-H.; Khin, E. S. W.; Bian, J.-S. Vasoconstrictive effect of hydrogen sulfide involves downregulation of cAMP in vascular smooth muscle cells Am. J. Physiol. Cell Physiol. 2008, 295, C1261-C1270 10.1152/ajpcell.00195.2008
52. Bausher, L. P.; Horio, B. Regulation of cyclic AMP production in adult human ciliary processes Exp. Eye Res. 1995, 60, 43-48 10.1016/S0014-4835(05)80082-X
53. Sears, M. L.; Neufeld, A. H. Editorial: Adrenergic modulation of the outflow of aqueous humor Invest. Ophthalmol. Visual Sci. 1975, 14, 83-86
54. Reitsamer, H. A.; Posey, M.; Kiel, J. W. Effects of a topical α2 adrenergic agonist on ciliary blood flow and aqueous production in rabbits Exp. Eye Res. 2006, 82, 405-415 10.1016/j.exer.2005.07.015
55. Toris, C. B.; Camras, C. B.; Yablonski, M. E. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients Am. J. Ophthalmol. 1999, 128, 8-14 10.1016/S0002-9394(99)00076-8
56. Baker, J. G.; Hill, S. J.; Summers, R. J. Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling Trends Pharmacol. Sci. 2011, 32, 227-234 10.1016/j.tips.2011.02.010
57. Prichard, B.; Gillam, P. Use of propranolol (Inderal) in treatment of hypertension Br. Med. J. 1964, 2, 725-727 10.1136/bmj.2.5411.725
58. Katz, I.; Hubbard, W.; Getson, A.; Gould, A. Intraocular pressure decrease in normal volunteers following timolol ophthalmic solution Invest. Ophthalmol. Visual Sci. 1976, 15, 489-492
59. Marquis, R. E.; Whitson, J. T. Management of glaucoma: focus on pharmacological therapy Drugs Aging 2005, 22, 1-21 10.2165/00002512-200522010-00001
60. Bromberg, B. B.; Gregory, D. S.; Sears, M. L. Beta-adrenergic receptors in ciliary processes of the rabbit Invest. Ophthalmol. Visual Sci. 1980, 19, 203-207
61. Phillips, C.; Howitt, G.; Rowlands, D. Propranolol as ocular hypotensive agent Br. J. Ophthalmol. 1967, 51, 222-226 10.1136/bjo.51.4.222
62. Coakes, R. L.; Brubaker, R. F. The mechanism of timolol in lowering intraocular pressure. In the normal eye Arch. Ophthalmol. 1978, 96, 2045-2048 10.1001/archopht.1978.03910060433007
63. Zimmerman, T. J.; Harbin, R.; Pett, M.; Kaufman, H. E. Timolol and facility of outflow Invest. Ophthalmol. Visual Sci. 1977, 16, 623-624
64. Wachter, S. B.; Gilbert, E. M. Beta-adrenergic receptors, from their discovery and characterization through their manipulation to beneficial clinical application Cardiology 2012, 122, 104-112 10.1159/000339271
65. McLaughlin, C. W.; Peart, D.; Purves, R. D.; Carré, D. A.; Peterson-Yantorno, K.; Mitchell, C. H.; Macknight, A. D.; Civan, M. M. Timolol may inhibit aqueous humor secretion by cAMP-independent action on ciliary epithelial cells Am. J. Physiol.: Cell Physiol. 2001, 281, C865-C875
66. Neufeld, A. H. Experimental studies on the mechanism of action of timolol Surv. Ophthalmol. 1979, 23, 363-370 10.1016/0039-6257(79)90229-7
67. Cracknell, K. P. B.; Grierson, I. Prostaglandin analogues in the anterior eye: Their pressure lowering action and side effects Exp. Eye Res. 2009, 88, 786-791 10.1016/j.exer.2008.08.022
68. Ricciotti, E.; FitzGerald, G. A. Prostaglandins and inflammation Arterioscler., Thromb., Vasc. Biol. 2011, 31, 986-1000 10.1161/ATVBAHA.110.207449
69. Von Euler, U. On the specific vaso-dilating and plain muscle stimulating substances from accessory genital glands in man and certain animals (prostaglandin and vesiglandin) J. Physiol. 1936, 88, 213-234 10.1113/jphysiol.1936.sp003433
70. Nilsson, S. F.; Drecoll, E.; Lütjen-Drecoll, E.; Toris, C. B.; Krauss, A. H.-P.; Kharlamb, A.; Nieves, A.; Guerra, T.; Woodward, D. F. The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey Invest. Ophthalmol. Visual Sci. 2006, 47, 4042-4049 10.1167/iovs.05-1627
71. Weinreb, R. N.; Toris, C. B.; Gabelt, B. A. T.; Lindsey, J. D.; Kaufman, P. L. Effects of prostaglandins on the aqueous humor outflow pathways Surv. Ophthalmol. 2002, 47 (Suppl. 1) S53-S64 10.1016/S0039-6257(02)00306-5
72. Toris, C. B.; Yablonski, M. E.; Wang, Y.-L.; Hayashi, M. Prostaglandin A2 increases uveoscleral outflow and trabecular outflow facility in the cat Exp. Eye Res. 1995, 61, 649-657 10.1016/S0014-4835(05)80015-6
73. Hinz, B.; Rösch, S.; Ramer, R.; Tamm, E. R.; Brune, K. Latanoprost induces matrix metalloproteinase-1 expression in human nonpigmented ciliary epithelial cells through a cyclooxygenase-2-dependent mechanism FASEB J. 2005, 19, 1929-1931 10.1096/fj.04-3626fje
74. Lindsey, J. D.; Kashiwagi, K.; Kashiwagi, F.; Weinreb, R. N. Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro Invest. Ophthalmol. Visual Sci. 1997, 38, 2214-2223
75. Ocklind, A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections Exp. Eye Res. 1998, 67, 179-191 10.1006/exer.1998.0508
76. Zhao, X.; Pearson, K. E.; Stephan, D. A.; Russell, P. Effects of prostaglandin analogues on human ciliary muscle and trabecular meshwork cells Invest. Ophthalmol. Visual Sci. 2003, 44, 1945-1952 10.1167/iovs.02-0920
77. Melamed, S.; Simon, G. J. B.; Levkovitch-Verbin, H. Selective laser trabeculoplasty as primary treatment for open-angle glaucoma: a prospective, nonrandomized pilot study Arch. Ophthalmol. 2003, 121, 957-960 10.1001/archopht.121.7.957
78. Damji, K. F.; Shah, K. C.; Rock, W. J.; Bains, H. S.; Hodge, W. G. Selective laser trabeculoplasty vargon laser trabeculoplasty: a prospective randomised clinical trial Br. J. Ophthalmol. 1999, 83, 718-722 10.1136/bjo.83.6.718
79. Johnson, D. H.; Johnson, M. How does nonpenetrating glaucoma surgery work? Aqueous outflow resistance and glaucoma surgery J. Glaucoma 2001, 10, 55-67 10.1097/00061198-200102000-00011
80. Ayala, M.; Chen, E. Comparison of selective laser trabeculoplasty (SLT) in primary open angle glaucoma and pseudoexfoliation glaucoma Clin. Ophthalmol. 2011, 5, 1469-1673 10.2147/OPTH.S25636
81. Gedde, S. J.; Schiffman, J. C.; Feuer, W. J.; Herndon, L. W.; Brandt, J. D.; Budenz, D. L. Treatment outcomes in the tube versus trabeculectomy (TVT) study after five years of follow-up Am. J. Ophthalmol. 2012, 153, 789-803.e2 10.1016/j.ajo.2011.10.026
82. Edmunds, B.; Thompson, J.; Salmon, J.; Wormald, R. The national survey of trabeculectomy. III. Early and late complications Eye 2002, 16, 297-303 10.1038/sj.eye.6700148
83. Spiegel, D.; Kobuch, K. Trabecular meshwork bypass tube shunt: initial case series Br. J. Ophthalmol. 2002, 86, 1228-1231 10.1136/bjo.86.11.1228
84. Francis, B. A.; Singh, K.; Lin, S. C.; Hodapp, E.; Jampel, H. D.; Samples, J. R.; Smith, S. D. Novel glaucoma procedures: a report by the American Academy of Ophthalmology Ophthalmology 2011, 118, 1466-1480 10.1016/j.ophtha.2011.03.028
85. Nolan, W. P.; Foster, P. J.; Devereux, J. G.; Uranchimeg, D.; Johnson, G. J.; Baasanhu, J. YAG laser iridotomy treatment for primary angle closure in east Asian eyes Br. J. Ophthalmol. 2000, 84, 1255-1259 10.1136/bjo.84.11.1255
86. Playfair, T. J.; Watson, P. G. Management of acute primary angle-closure glaucoma: a long-term follow-up of the results of peripheral iridectomy used as an initial procedure Br. J. Ophthalmol. 1979, 63, 17-22 10.1136/bjo.63.1.17
87. Dautriche, C. N.; Xie, Y.; Sharfstein, S. T. Walking through trabecular meshwork biology: Toward engineering design of outflow physiology Biotechnol. Adv. 2014, 32, 971-983 10.1016/j.biotechadv.2014.04.012
88. Yamamoto, T.; Kitazawa, Y. Vascular pathogenesis of normal-tension glaucoma: a possible pathogenetic factor, other than intraocular pressure, of glaucomatous optic neuropathy Prog. Retinal Eye Res. 1998, 17, 127-143 10.1016/S1350-9462(97)00009-8
89. Sena, D. F.; Lindsley, K. Neuroprotection for treatment of glaucoma in adults Cochrane Database Syst. Rev. 2013, 2, CD006539 10.1002/14651858.CD006539.pub3
90. Chua, B.; Goldberg, I. Neuroprotective agents in glaucoma therapy: recent developments and future directions Expert Rev. Ophthalmol. 2010, 5, 627-636 10.1586/eop.10.55
91. Leung, T.; Chen, X.-Q.; Manser, E.; Lim, L. The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton Mol. Cell. Biol. 1996, 16, 5313-5327
92. Amano, M.; Ito, M.; Kimura, K.; Fukata, Y.; Chihara, K.; Nakano, T.; Matsuura, Y.; Kaibuchi, K. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase) J. Biol. Chem. 1996, 271, 20246-20249 10.1074/jbc.271.34.20246
93. Riento, K.; Ridley, A. J. Rocks: multifunctional kinases in cell behaviour Nat. Rev. Mol. Cell Biol. 2003, 4, 446-456 10.1038/nrm1128
94. Wang, S. K.; Chang, R. T. An emerging treatment option for glaucoma: Rho kinase inhibitors Clin. Ophthalmol. 2014, 8, 883-890 10.2147/OPTH.S41000
95. Satoh, K.; Fukumoto, Y.; Shimokawa, H. Rho-kinase: important new therapeutic target in cardiovascular diseases Am. J. Physiol. Heart Circ. Physiol. 2011, 301, H287-H296 10.1152/ajpheart.00327.2011
96. Mueller, B. K.; Mack, H.; Teusch, N. Rho kinase, a promising drug target for neurological disorders Nat. Rev. Drug Discovery 2005, 4, 387-398 10.1038/nrd1719
97. Jacobs, M.; Hayakawa, K.; Swenson, L.; Bellon, S.; Fleming, M.; Taslimi, P.; Doran, J. The structure of dimeric ROCK I reveals the mechanism for ligand selectivity J. Biol. Chem. 2006, 281, 260-268 10.1074/jbc.M508847200
98. Nakagawa, O.; Fujisawa, K.; Ishizaki, T.; Saito, Y.; Nakao, K.; Narumiya, S. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice FEBS Lett. 1996, 392, 189-193 10.1016/0014-5793(96)00811-3
99. Hahmann, C.; Schroeter, T. Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity Cell. Mol. Life Sci. 2010, 67, 171-177 10.1007/s00018-009-0189-x
100. Yoneda, A.; Multhaupt, H. A. B.; Couchman, J. R. The Rho kinases I and II regulate different aspects of myosin II activity J. Cell Biol. 2005, 170, 443-453 10.1083/jcb.200412043
101. Yoneda, A.; Ushakov, D.; Multhaupt, H. A.; Couchman, J. R. Fibronectin matrix assembly requires distinct contributions from Rho kinases I and-II Mol. Biol. Cell 2007, 18, 66-75 10.1091/mbc.E06-08-0684
102. Kjøller, L.; Hall, A. Signaling to Rho GTPases Exp. Cell Res. 1999, 253, 166-179 10.1006/excr.1999.4674
103. Fukata, Y.; Kaibuchi, K.; Amano, M.; Kaibuchi, K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells Trends Pharmacol. Sci. 2001, 22, 32-39 10.1016/S0165-6147(00)01596-0
104. Fukiage, C.; Mizutani, K.; Kawamoto, Y.; Azuma, M.; Shearer, T. R. Involvement of phosphorylation of myosin phosphatase by ROCK in trabecular meshwork and ciliary muscle contraction Biochem. Biophys. Res. Commun. 2001, 288, 296-300 10.1006/bbrc.2001.5751
105. Whitlock, N. A.; Harrison, B.; Mixon, T.; Yu, X.-Q.; Wilson, A.; Gerhardt, B.; Eberhart, D. E.; Abuin, A.; Rice, D. S. Decreased intraocular pressure in mice following either pharmacological or genetic inhibition of ROCK J. Ocul. Pharmacol. Ther. 2009, 25, 187-194 10.1089/jop.2008.0142
106. Aznar, S.; Fernández-Valerón, P.; Espina, C.; Lacal, J. C. Rho GTPases: potential candidates for anticancer therapy Cancer Lett. 2004, 206, 181-191 10.1016/j.canlet.2003.08.035
107. Noda, K.; Nakajima, S.; Godo, S.; Saito, H.; Ikeda, S.; Shimizu, T.; Enkhjargal, B.; Fukumoto, Y.; Tsukita, S.; Yamada, T.; Katagiri, H.; Shimokawa, H. Rho-kinase inhibition ameliorates metabolic disorders through activation of AMPK pathway in mice PLoS One 2014, 9, e110446 10.1371/journal.pone.0110446
108. Guan, R.; Xu, X.; Chen, M.; Hu, H.; Ge, H.; Wen, S.; Zhou, S.; Pi, R. Advances in the studies of roles of Rho/Rho-kinase in diseases and the development of its inhibitors Eur. J. Med. Chem. 2013, 70, 613-622 10.1016/j.ejmech.2013.10.048
109. Pan, P.; Shen, M.; Yu, H.; Li, Y.; Li, D.; Hou, T. Advances in the development of Rho-associated protein kinase (ROCK) inhibitors Drug Discovery Today 2013, 18, 1323-1333 10.1016/j.drudis.2013.09.010
110. LoGrasso, P. V.; Feng, Y. Rho kinase (ROCK) inhibitors and their application to inflammatory disorders Curr. Top. Med. Chem. 2009, 9, 704-723 10.2174/156802609789044452
111. Tamura, M.; Nakao, H.; Yoshizaki, H.; Shiratsuchi, M.; Shigyo, H.; Yamada, H.; Ozawa, T.; Totsuka, J.; Hidaka, H. Development of specific Rho-kinase inhibitors and their clinical application Biochim. Biophys. Acta, Proteins Proteomics 2005, 1754, 245-252 10.1016/j.bbapap.2005.06.015
112. Hidaka, H.; Inagaki, M.; Kawamoto, S.; Sasaki, Y. Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide-dependent protein kinase and protein kinase C Biochemistry 1984, 23, 5036-5041 10.1021/bi00316a032
113. Ono-Saito, N.; Niki, I.; Hidaka, H. H-Series protein kinase inhibitors and potential clinical applications Pharmacol. Ther. 1999, 82, 123-131 10.1016/S0163-7258(98)00070-9
114. Davies, S.; Reddy, H.; Caivano, M.; Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors Biochem. J. 2000, 351, 95-105 10.1042/0264-6021:3510095
115. Shibuya, M.; Hirai, S.; Seto, M.; Satoh, S.-i.; Ohtomo, E.; Group, F. I. S. S. Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial J. Neurol. Sci. 2005, 238, 31-39 10.1016/j.jns.2005.06.003
116. Sumi, K.; Inoue, Y.; Nishio, M.; Naito, Y.; Hosoya, T.; Suzuki, M.; Hidaka, H. IOP-lowering effect of isoquinoline-5-sulfonamide compounds in ocular normotensive monkeys Bioorg. Med. Chem. Lett. 2014, 24, 831-834 10.1016/j.bmcl.2013.12.085
117. Yamamoto, K.; Maruyama, K.; Himori, N.; Omodaka, K.; Yokoyama, Y.; Shiga, Y.; Morin, R.; Nakazawa, T. The novel Rho kinase (ROCK) inhibitor K-115: A new candidate drug for neuroprotective treatment in glaucoma Invest. Ophthalmol. Vis. Sci. 2014, 55, 7126-7136 10.1167/iovs.13-13842
118. Lavogina, D.; Kalind, K.; Bredihhina, J.; Hurt, M.; Vaasa, A.; Kasari, M.; Enkvist, E.; Raidaru, G.; Uri, A. Conjugates of 5-isoquinolinesulfonylamides and oligo-D-arginine possess high affinity and selectivity towards Rho kinase (ROCK) Bioorg. Med. Chem. Lett. 2012, 22, 3425-3430 10.1016/j.bmcl.2012.03.101
119. Ray, P.; Wright, J.; Adam, J.; Bennett, J.; Boucharens, S.; Black, D.; Cook, A.; Brown, A. R.; Epemolu, O.; Fletcher, D.; Haunso, A.; Huggett, M.; Jones, P.; Laats, S.; Lyons, A.; Mestres, J.; de Man, J.; Morphy, R.; Rankovic, Z.; Sherborne, B.; Sherry, L.; van Straten, N.; Westwood, P.; Zaman, G. Z. R. Fragment-based discovery of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors Bioorg. Med. Chem. Lett. 2011, 21, 97-101 10.1016/j.bmcl.2010.11.060
120. Iwakubo, M.; Takami, A.; Okada, Y.; Kawata, T.; Tagami, Y.; Sato, M.; Sugiyama, T.; Fukushima, K.; Taya, S.; Amano, M.; Kaibuchi, K.; Iijima, H. Design and synthesis of Rho kinase inhibitors (III) Bioorg. Med. Chem. 2007, 15, 1022-1033 10.1016/j.bmc.2006.10.028
121. Wu, F.; Büttner, F. H.; Chen, R.; Hickey, E.; Jakes, S.; Kaplita, P.; Kashem, M. A.; Kerr, S.; Kugler, S.; Paw, Z. Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account Bioorg. Med. Chem. Lett. 2010, 20, 3235-3239 10.1016/j.bmcl.2010.04.070
122. Ginn, J. D.; Bosanac, T.; Chen, R.; Cywin, C.; Hickey, E.; Kashem, M.; Kerr, S.; Kugler, S.; Li, X.; Prokopowicz, A. Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 2, optimization for blood pressure reduction in spontaneously hypertensive rats Bioorg. Med. Chem. Lett. 2010, 20, 5153-5156 10.1016/j.bmcl.2010.07.014
123. Bosanac, T.; Hickey, E. R.; Ginn, J.; Kashem, M.; Kerr, S.; Kugler, S.; Li, X.; Olague, A.; Schlyer, S.; Young, E. R. Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 3, aryl substituted pyrrolidines Bioorg. Med. Chem. Lett. 2010, 20, 3746-3749 10.1016/j.bmcl.2010.04.069
124. Li, R.; Martin, M. P.; Liu, Y.; Wang, B.; Patel, R. A.; Zhu, J.-Y.; Sun, N.; Pireddu, R.; Lawrence, N. J.; Li, J.; Haura, E. B.; Sung, S.-S.; Guida, W. C.; Schonbrunn, E.; Sebti, S. M. Fragment-based and structure-guided discovery and optimization of Rho kinase inhibitors J. Med. Chem. 2012, 55, 2474-2478 10.1021/jm201289r
125. Ho, K.-K.; Beasley, J. R.; Belanger, L.; Black, D.; Chan, J.-H.; Dunn, D.; Hu, B.; Klon, A.; Kultgen, S. G.; Ohlmeyer, M. Triazine and pyrimidine based ROCK inhibitors with efficacy in spontaneous hypertensive rat model Bioorg. Med. Chem. Lett. 2009, 19, 6027-6031 10.1016/j.bmcl.2009.09.046
126. Henderson, A. J.; Hadden, M.; Guo, C.; Douglas, N.; Decornez, H.; Hellberg, M. R.; Rusinko, A.; McLaughlin, M.; Sharif, N.; Drace, C.; Patil, R. 2,3-Diaminopyrazines as Rho kinase inhibitors Bioorg. Med. Chem. Lett. 2010, 20, 1137-1140 10.1016/j.bmcl.2009.12.012
127. Uehata, M.; Ishizaki, T.; Satoh, H.; Ono, T.; Kawahara, T.; Morishita, T.; Tamakawa, H.; Yamagami, K.; Inui, J.; Maekawa, M.; Narumiya, S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension Nature 1997, 389, 990-994 10.1038/40187
128. Tokushige, H.; Inatani, M.; Nemoto, S.; Sakaki, H.; Katayama, K.; Uehata, M.; Tanihara, H. Effects of topical administration of Y-39983, a selective Rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys Invest. Ophthalmol. Visual Sci. 2007, 48, 3216-3222 10.1167/iovs.05-1617
129. Chen, H.-H.; Namil, A.; Severns, B.; Ward, J.; Kelly, C.; Drace, C.; McLaughlin, M. A.; Yacoub, S.; Li, B.; Patil, R. In vivo optimization of 2,3-diaminopyrazine Rho kinase inhibitors for the treatment of glaucoma Bioorg. Med. Chem. Lett. 2014, 24, 1875-1879 10.1016/j.bmcl.2014.03.017
130. Yin, Y.; Cameron, M. D.; Lin, L.; Khan, S.; Schröter, T.; Grant, W.; Pocas, J.; Chen, Y. T.; Schürer, S.; Pachori, A. Discovery of potent and selective urea-based ROCK inhibitors and their effects on intraocular pressure in rats ACS Med. Chem. Lett. 2010, 1, 175-179 10.1021/ml1000382
131. Davis, R. L.; Kahraman, M.; Prins, T. J.; Beaver, Y.; Cook, T. G.; Cramp, J.; Cayanan, C. S.; Gardiner, E. M. M.; McLaughlin, M. A.; Clark, A. F.; Hellberg, M. R.; Shiau, A. K.; Noble, S. A.; Borchardt, A. J. Benzothiophene containing Rho kinase inhibitors: efficacy in an animal model of glaucoma Bioorg. Med. Chem. Lett. 2010, 20, 3361-3366 10.1016/j.bmcl.2010.04.020
132. Feng, Y.; Cameron, M. D.; Frackowiak, B.; Griffin, E.; Lin, L.; Ruiz, C.; Schröter, T.; LoGrasso, P. Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II Bioorg. Med. Chem. Lett. 2007, 17, 2355-2360 10.1016/j.bmcl.2006.12.043
133. Goodman, K. B.; Cui, H.; Dowdell, S. E.; Gaitanopoulos, D. E.; Ivy, R. L.; Sehon, C. A.; Stavenger, R. A.; Wang, G. Z.; Viet, A. Q.; Xu, W. Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors J. Med. Chem. 2007, 50, 6-9 10.1021/jm0609014
134. Sehon, C. A.; Wang, G. Z.; Viet, A. Q.; Goodman, K. B.; Dowdell, S. E.; Elkins, P. A.; Semus, S. F.; Evans, C.; Jolivette, L. J.; Kirkpatrick, R. B. Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases J. Med. Chem. 2008, 51, 6631-6634 10.1021/jm8005096
135. Shaw, D.; Hollingworth, G.; Soldermann, N.; Sprague, E.; Schuler, W.; Vangrevelinghe, E.; Duggan, N.; Thomas, M.; Kosaka, T.; Waters, N.; van Eis, M. J. Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension Bioorg. Med. Chem. Lett. 2014, 24, 4812-4817 10.1016/j.bmcl.2014.09.002
136. Stavenger, R. A.; Cui, H.; Dowdell, S. E.; Franz, R. G.; Gaitanopoulos, D. E.; Goodman, K. B.; Hilfiker, M. A.; Ivy, R. L.; Leber, J. D.; Marino, J. P. Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity J. Med. Chem. 2007, 50, 2-5 10.1021/jm060873p
137. Pireddu, R.; Forinash, K.; Sun, N. N.; Martin, M. P.; Sung, S.-S.; Alexander, B.; Zhu, J.-Y.; Guida, W. C.; Schönbrunn, E.; Sebti, S. M.; Lawrence, N. J. Abstract 3904: Pyridylthiazole-based ureas as inhibitors of Rho-associated protein kinases Cancer Res. 2012, 72, 3904 10.1158/1538-7445.AM2012-3904
138. Patel, R. A.; Forinash, K. D.; Pireddu, R.; Sun, Y.; Sun, N.; Martin, M. P.; Schönbrunn, E.; Lawrence, N. J.; Sebti, S. M. RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer Cancer Res. 2012, 72, 5025-5034 10.1158/0008-5472.CAN-12-0954
139. Schirok, H.; Kast, R.; Figueroa-Pérez, S.; Bennabi, S.; Gnoth, M. J.; Feurer, A.; Heckroth, H.; Thutewohl, M.; Paulsen, H.; Knorr, A. Design and synthesis of potent and selective azaindole-based Rho kinase (ROCK) inhibitors ChemMedChem 2008, 3, 1893-1904 10.1002/cmdc.200800211
140. Chen, Y. T.; Bannister, T. D.; Weiser, A.; Griffin, E.; Lin, L.; Ruiz, C.; Cameron, M. D.; Schürer, S.; Duckett, D.; Schröter, T.; LoGrasso, P.; Feng, Y. Chroman-3-amides as potent Rho kinase inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 6406-6409 10.1016/j.bmcl.2008.10.080
141. Feng, Y.; Yin, Y.; Weiser, A.; Griffin, E.; Cameron, M. D.; Lin, L.; Ruiz, C.; Schürer, S. C.; Inoue, T.; Rao, P. V. Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors J. Med. Chem. 2008, 51, 6642-6645 10.1021/jm800986w
142. Rao, P. V.; Deng, P.-F.; Kumar, J.; Epstein, D. L. Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632 Invest. Ophthalmol. Visual Sci. 2001, 42, 1029-1037
143. Harrison, B. A.; Almstead, Z. Y.; Burgoon, H.; Gardyan, M.; Goodwin, N. C.; Healy, J.; Liu, Y.; Mabon, R.; Marinelli, B.; Samala, L. Discovery and development of LX7101, a dual LIM-kinase and ROCK inhibitor for the treatment of glaucoma ACS Med. Chem. Lett. 2015, 6, 84-88 10.1021/ml500367g
144. Lu, Z.; Overby, D. R.; Scott, P. A.; Freddo, T. F.; Gong, H. The mechanism of increasing outflow facility by Rho-kinase inhibition with Y-27632 in bovine eyes Exp. Eye Res. 2008, 86, 271-281 10.1016/j.exer.2007.10.018
145. Rao, P. V.; Deng, P.; Sasaki, Y.; Epstein, D. L. Regulation of myosin light chain phosphorylation in the trabecular meshwork: role in aqueous humour outflow facility Exp. Eye Res. 2005, 80, 197-206 10.1016/j.exer.2004.08.029
146. Honjo, M.; Inatani, M.; Kido, N.; Sawamura, T.; Yue, B. Y. J. T.; Honda, Y.; Tanihara, H. A myosin light chain kinase inhibitor, ML-9, lowers the intraocular pressure in rabbit eyes Exp. Eye Res. 2002, 75, 135-142 10.1006/exer.2002.2009
147. Harrison, B. A.; Whitlock, N. A.; Voronkov, M. V.; Almstead, Z. Y.; Gu, K.-j.; Mabon, R.; Gardyan, M.; Hamman, B. D.; Allen, J.; Gopinathan, S. Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma J. Med. Chem. 2009, 52, 6515-6518 10.1021/jm901226j
148. Sugiyama, T.; Shibata, M.; Kajiura, S.; Okuno, T.; Tonari, M.; Oku, H.; Ikeda, T. Effects of fasudil, a Rho-associated protein kinase inhibitor, on optic nerve head blood flow in rabbits Invest. Ophthalmol. Visual Sci. 2011, 52, 64-69 10.1167/iovs.10-5265
149. Tokushige, H.; Waki, M.; Takayama, Y.; Tanihara, H. Effects of Y-39983, a selective Rho-associated protein kinase inhibitor, on blood flow in optic nerve head in rabbits and axonal regeneration of retinal ganglion cells in rats Curr. Eye Res. 2011, 36, 964-970 10.3109/02713683.2011.599106
150. Song, H.; Gao, D. Fasudil, a Rho-associated protein kinase inhibitor, attenuates retinal ischemia and reperfusion injury in rats Int. J. Mol. Med. 2011, 28, 193-198 10.3892/ijmm.2011.659
151. Kitaoka, Y.; Kitaoka, Y.; Kumai, T.; Lam, T. T.; Kuribayashi, K.; Isenoumi, K.; Munemasa, Y.; Motoki, M.; Kobayashi, S.; Ueno, S. Involvement of RhoA and possible neuroprotective effect of fasudil, a Rho kinase inhibitor, in NMDA-induced neurotoxicity in the rat retina Brain Res. 2004, 1018, 111-118 10.1016/j.brainres.2004.05.070
152. Hirata, A.; Inatani, M.; Inomata, Y.; Yonemura, N.; Kawaji, T.; Honjo, M.; Tanihara, H. Y-27632, a Rho-associated protein kinase inhibitor, attenuates neuronal cell death after transient retinal ischemia Graefe's Arch. Clin. Exp. Ophthalmol. 2008, 246, 51-59 10.1007/s00417-007-0666-6
153. Lingor, P.; Tönges, L.; Pieper, N.; Bermel, C.; Barski, E.; Planchamp, V.; Bähr, M. ROCK inhibition and CNTF interact on intrinsic signalling pathways and differentially regulate survival and regeneration in retinal ganglion cells Brain 2008, 131, 250-263 10.1093/brain/awm284
154. Honjo, M.; Tanihara, H.; Kameda, T.; Kawaji, T.; Yoshimura, N.; Araie, M. Potential role of Rho-associated protein kinase inhibitor Y-27632 in glaucoma filtration surgery Invest. Ophthalmol. Visual Sci. 2007, 48, 5549-5557 10.1167/iovs.07-0878
155. Chen, J.; Runyan, S. A.; Robinson, M. R. Novel ocular antihypertensive compounds in clinical trials Clin. Ophthalmol. 2011, 5, 667-677 10.2147/OPTH.S15971
156. Boland, S.; Defert, O.; Alen, J.; Bourin, A.; Castermans, K.; Kindt, N.; Boumans, N.; Panitti, L.; Van de Velde, S.; Stalmans, I. 3-[2-(Aminomethyl)-5-[(pyridin-4-yl) carbamoyl] phenyl] benzoates as soft ROCK inhibitors Bioorg. Med. Chem. Lett. 2013, 23, 6442-6446 10.1016/j.bmcl.2013.09.040
157. deLong, M. A.; Yingling, J.; Lin, C.-W.; Sherman, B.; Sturdivant, J.; Heintzelman, G.; Lathem, C.; van Haarlem, T.; Kopczynski, C. Discovery and SAR of a class of ocularly-active compounds displaying a dual mechanism of activity for the treatment of glaucoma Invest. Ophthalmol. Visual Sci. 2012, 53, 3867
158. Kvanta, A.; Seregard, S.; Sejersen, S.; Kull, B.; Fredholm, B. B. Localization of Adenosine Receptor Messenger RNAs in the Rat Eye Exp. Eye Res. 1997, 65, 595-602 10.1006/exer.1996.0352
159. Fleischhauer, J.; Mitchell, C.; Stamer, W.; Karl, M.; Peterson-Yantorno, K.; Civan, M. Common actions of adenosine receptor agonists in modulating human trabecular meshwork cell transport J. Membr. Biol. 2003, 193, 121-136 10.1007/s00232-002-2013-5
160. Karl, M. O.; Fleischhauer, J. C.; Stamer, W. D.; Peterson-Yantorno, K.; Mitchell, C. H.; Stone, R. A.; Civan, M. M. Differential P1-purinergic modulation of human Schlemm's canal inner-wall cells Am. J. Physiol.: Cell Physiol. 2005, 288, C784-C794 10.1152/ajpcell.00333.2004
161. Avila, M. Y.; Stone, R. A.; Civan, M. M. A1-, A2A- and A3-subtype adenosine receptors modulate intraocular pressure in the mouse Br. J. Pharmacol. 2001, 134, 241-245 10.1038/sj.bjp.0704267
162. Fredholm, B. B. Adenosine receptors as drug targets Exp. Cell Res. 2010, 316, 1284-1288 10.1016/j.yexcr.2010.02.004
163. Husain, S.; Shearer, T. W.; Crosson, C. E. Mechanisms linking adenosine A1 receptors and extracellular signal-regulated kinase 1/2 activation in human trabecular meshwork cells J. Pharmacol. Exp. Ther. 2007, 320, 258-265 10.1124/jpet.106.110981
164. Agarwal, R.; Agarwal, P. Newer targets for modulation of intraocular pressure: focus on adenosine receptor signaling pathways Expert Opin. Ther. Targets 2014, 18, 527-539 10.1517/14728222.2014.888416
165. Zhong, Y.; Yang, Z.; Huang, W.-C.; Luo, X. Adenosine, adenosine receptors and glaucoma: An updated overview Biochim. Biophys. Acta, Gen. Subj. 2013, 1830, 2882-2890 10.1016/j.bbagen.2013.01.005
166. Drury, A.; Szent-Györgyi, A. v. The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart J. Physiol. 1929, 68, 213-237 10.1113/jphysiol.1929.sp002608
167. Chen, J.-F.; Eltzschig, H. K.; Fredholm, B. B. Adenosine receptors as drug targets-what are the challenges? Nat. Rev. Drug Discovery 2013, 12, 265-286 10.1038/nrd3955
168. Jacobson, K. A.; Van Galen, P. J.; Williams, M. Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential J. Med. Chem. 1992, 35, 407-422 10.1021/jm00081a001
169. Müller, C. E.; Jacobson, K. A. Recent developments in adenosine receptor ligands and their potential as novel drugs Biochim. Biophys. Acta, Biomembr. 2011, 1808, 1290-1308 10.1016/j.bbamem.2010.12.017
170. Haskó, G.; Linden, J.; Cronstein, B.; Pacher, P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases Nat. Rev. Drug Discovery 2008, 7, 759-770 10.1038/nrd2638
171. Fredholm, B. B.; Arslan, G.; Halldner, L.; Kull, B.; Schulte, G.; Wasserman, W. Structure and function of adenosine receptors and their genes Naunyn-Schmiedeberg's Arch. Pharmacol. 2000, 362, 364-374 10.1007/s002100000313
172. Lebon, G.; Warne, T.; Edwards, P. C.; Bennett, K.; Langmead, C. J.; Leslie, A. G. W.; Tate, C. G. Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation Nature 2011, 474, 521-525 10.1038/nature10136
173. Doré, A. S.; Robertson, N.; Errey, J. C.; Ng, I.; Hollenstein, K.; Tehan, B.; Hurrell, E.; Bennett, K.; Congreve, M.; Magnani, F.; Tate, C. G.; Weir, M.; Marshall, F. H. Structure of the adenosine A2A receptor in complex with ZM241385 and the xanthines XAC and caffeine Structure 2011, 19, 1283-1293 10.1016/j.str.2011.06.014
174. Yan, L.; Burbiel, J. C.; Maaß, A.; Müller, C. E. Adenosine receptor agonists: from basic medicinal chemistry to clinical development Expert Opin. Emerging Drugs 2003, 8, 537-576 10.1517/14728214.8.2.537
175. Zhang, K.; Zhang, L.; Weinreb, R. N. Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma Nat. Rev. Drug Discovery 2012, 11, 541-559 10.1038/nrd3745
176. Konno, T.; Murakami, A.; Uchibori, T.; Nagai, A.; Kogi, K.; Nakahata, N. Involvement of adenosine A2a receptor in intraocular pressure decrease induced by 2-(1-octyn-1-yl) adenosine or 2-(6-cyano-1-hexyn-1-yl) adenosine J. Pharmacol. Sci. 2005, 97, 501-509 10.1254/jphs.FP0040730
177. Daly, J. Caffeine analogs: biomedical impact Cell. Mol. Life Sci. 2007, 64, 2153-2169 10.1007/s00018-007-7051-9
178. Okamura, T.; Kurogi, Y.; Hashimoto, K.; Sato, S.; Nishikawa, H.; Kiryu, K.; Nagao, Y. Structure-activity relationships of adenosine A3 receptor ligands: new potential therapy for the treatment of glaucoma Bioorg. Med. Chem. Lett. 2004, 14, 3775-3779 10.1016/j.bmcl.2004.04.099
179. Li, A.-H.; Moro, S.; Melman, N.; Ji, X.-d.; Jacobson, K. A. Structure-activity relationships and molecular modeling of 3, 5-diacyl-2, 4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists J. Med. Chem. 1998, 41, 3186-3201 10.1021/jm980093j
180. Wang, Z.; Do, C. W.; Avila, M. Y.; Peterson-Yantorno, K.; Stone, R. A.; Gao, Z.-G.; Joshi, B.; Besada, P.; Jeong, L. S.; Jacobson, K. A.; Civan, M. M. Nucleoside-derived antagonists to A3 adenosine receptors lower mouse intraocular pressure and act across species Exp. Eye Res. 2010, 90, 146-154 10.1016/j.exer.2009.10.001
181. Crosson, C. E. Adenosine receptor activation modulates intraocular pressure in rabbits J. Pharmacol. Exp. Ther. 1995, 273, 320-326
182. Crosson, C. E.; Sloan, C. F.; Yates, P. W. Modulation of conventional outflow facility by the adenosine A1 agonist N6-cyclohexyladenosine Invest. Ophthalmol. Visual Sci. 2005, 46, 3795-3799 10.1167/iovs.05-0421
183. Tian, B.; Gabelt, B. A. T.; Crosson, C. E.; Kaufman, P. L. Effects of adenosine agonists on intraocular pressure and aqueous humor dynamics in cynomolgus monkeys Exp. Eye Res. 1997, 64, 979-989 10.1006/exer.1997.0296
184. Shearer, T. W.; Crosson, C. E. Adenosine A1 receptor modulation of MMP-2 secretion by trabecular meshwork cells Invest. Ophthalmol. Visual Sci. 2002, 43, 3016-3020
185. Keller, K. E.; Aga, M.; Bradley, J. M.; Kelley, M. J.; Acott, T. S. Extracellular matrix turnover and outflow resistance Exp. Eye Res. 2009, 88, 676-682 10.1016/j.exer.2008.11.023
186. Bradley, J.; Vranka, J.; Colvis, C. M.; Conger, D. M.; Alexander, J. P.; Fisk, A. S.; Samples, J. R.; Acott, T. S. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture Invest. Ophthalmol. Visual Sci. 1998, 39, 2649-2658
187. Karl, M. O.; Peterson-Yantorno, K.; Civan, M. M. Cell-specific differential modulation of human trabecular meshwork cells by selective adenosine receptor agonists Exp. Eye Res. 2007, 84, 126-134 10.1016/j.exer.2006.09.007
188. Al-Aswad, L. A.; Gong, H.; Lee, D.; O'Donnell, M. E.; Brandt, J. D.; Ryan, W. J.; Schroeder, A.; Erickson, K. A. Effects of Na-K-2Cl cotransport regulators on outflow facility in calf and human eyes in vitro Invest. Ophthalmol. Visual Sci. 1999, 40, 1695-1701
189. - channels of nonpigmented ciliary epithelial cells Am. J. Physiol.: Cell Physiol. 1999, 276, C659-C666
190. Yang, H.; Avila, M. Y.; Peterson-Yantorno, K.; Coca-Prados, M.; Stone, R. A.; Jacobson, K. A.; Civan, M. M. The cross-species A3 adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure Curr. Eye Res. 2005, 30, 747-754 10.1080/02713680590953147
191. 3 adenosine receptors reduces mouse intraocular pressure Invest. Ophthalmol. Visual Sci. 2002, 43, 3021-3026
192. Avni, I.; Garzozi, H. J.; Barequet, I. S.; Segev, F.; Varssano, D.; Sartani, G.; Chetrit, N.; Bakshi, E.; Zadok, D.; Tomkins, O. Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial Ophthalmology 2010, 117, 1287-1293 10.1016/j.ophtha.2009.11.029
193. Jacobson, K. A.; von Lubitz, D. K. J. E.; Daly, J. W.; Fredholm, B. B. Adenosine receptor ligands: differences with acute versus chronic treatment Trends Pharmacol. Sci. 1996, 17, 108-113 10.1016/0165-6147(96)10002-X
194. Mitchell, C. H.; Lu, W.; Hu, H.; Zhang, X.; Reigada, D.; Zhang, M. The P2 × 7 receptor in retinal ganglion cells: A neuronal model of pressure-induced damage and protection by a shifting purinergic balance Purinergic Signalling 2008, 4, 313-321 10.1007/s11302-008-9125-z
195. Zhang, X.; Zhang, M.; Laties, A. M.; Mitchell, C. H. Stimulation of P2 × 7 receptors elevates Ca2+ and kills retinal ganglion cells Invest. Ophthalmol. Visual Sci. 2005, 46, 2183-2191 10.1167/iovs.05-0052
196. Kakurai, K.; Sugiyama, T.; Kurimoto, T.; Oku, H.; Ikeda, T. Involvement of P2X7 receptors in retinal ganglion cell death after optic nerve crush injury in rats Neurosci. Lett. 2013, 534, 237-241 10.1016/j.neulet.2012.11.060
197. Niyadurupola, N.; Sidaway, P.; Ma, N.; Rhodes, J. D.; Broadway, D. C.; Sanderson, J. P2X7 receptor activation mediates retinal ganglion cell death in a human retina model of ischemic neurodegeneration Invest. Ophthalmol. Visual Sci. 2013, 54, 2163-2170 10.1167/iovs.12-10968
198. Ullian, E.; Barkis, W.; Chen, S.; Diamond, J.; Barres, B. Invulnerability of retinal ganglion cells to NMDA excitotoxicity Mol. Cell. Neurosci. 2004, 26, 544-557 10.1016/j.mcn.2004.05.002
199. Sucher, N. J.; Lipton, S. A.; Dreyer, E. B. Molecular basis of glutamate toxicity in retinal ganglion cells Vision Res. 1997, 37, 3483-3493 10.1016/S0042-6989(97)00047-3
200. Vorwerk, C. K.; Gorla, M. S.; Dreyer, E. B. An experimental basis for implicating excitotoxicity in glaucomatous optic neuropathy Surv. Ophthalmol. 1999, 43, S142-S150 10.1016/S0039-6257(99)00017-X
201. Hartwick, A. T.; Lalonde, M. R.; Barnes, S.; Baldridge, W. H. Adenosine A1-receptor modulation of glutamate-induced calcium influx in rat retinal ganglion cells Invest. Ophthalmol. Visual Sci. 2004, 45, 3740-3748 10.1167/iovs.04-0214
202. Zhang, X.; Zhang, M.; Laties, A. M.; Mitchell, C. H. Balance of purines may determine life or death of retinal ganglion cells as A3 adenosine receptors prevent loss following P2X7 receptor stimulation J. Neurochem. 2006, 98, 566-575 10.1111/j.1471-4159.2006.03900.x
203. Zhang, M.; Hu, H.; Zhang, X.; Lu, W.; Lim, J.; Eysteinsson, T.; Jacobson, K. A.; Laties, A. M.; Mitchell, C. H. The A3 adenosine receptor attenuates the calcium rise triggered by NMDA receptors in retinal ganglion cells Neurochem. Int. 2010, 56, 35-41 10.1016/j.neuint.2009.08.011
204. Polska, E.; Ehrlich, P.; Luksch, A.; Fuchsjäger-Mayrl, G.; Schmetterer, L. Effects of adenosine on intraocular pressure, optic nerve head blood flow, and choroidal blood flow in healthy humans Invest. Ophthalmol. Visual Sci. 2003, 44, 3110-3114 10.1167/iovs.02-1133
205. Sugiyama, T.; Shibata, M.; Kojima, S.; Ikeda, T. Optic nerve head blood flow in glaucoma. In The Mystery of Glaucoma; Kubena, T., Ed. InTech: Rijeka, Croatia, 2011; pp 207-218.
206. Flammer, J.; Orgül, S. Optic nerve blood-flow abnormalities in glaucoma Prog. Retinal Eye Res. 1998, 17, 267-289 10.1016/S1350-9462(97)00006-2
207. Wang, L.; Cull, G. A.; Piper, C.; Burgoyne, C. F.; Fortune, B. Anterior and posterior optic nerve head blood flow in nonhuman primate experimental glaucoma model measured by laser speckle imaging technique and microsphere method Invest. Ophthalmol. Visual Sci. 2012, 53, 8303-8309 10.1167/iovs.12-10911
208. Hirao, M.; Oku, H.; Goto, W.; Sugiyama, T.; Kobayashi, T.; Ikeda, T. Effects of adenosine on optic nerve head circulation in rabbits Exp. Eye Res. 2004, 79, 729-735 10.1016/j.exer.2004.08.008
209. Von Lubitz, D. K.; Lin, R. C.-S.; Popik, P.; Carter, M. F.; Jacobson, K. A. Adenosine A3 receptor stimulation and cerebral ischemia Eur. J. Pharmacol. 1994, 263, 59-67 10.1016/0014-2999(94)90523-1
210. Santiago, A. R.; Baptista, F. I.; Santos, P. F.; Cristóvão, G.; Ambrósio, A. F.; Cunha, R. A.; Gomes, C. A. Role of microglia adenosine A 2A receptors in retinal and brain neurodegenerative diseases Mediators Inflammation 2014, 2014, 465694 10.1155/2014/465694
211. Pal, S.; Choi, W. J.; Choe, S. A.; Heller, C. L.; Gao, Z.-G.; Chinn, M.; Jacobson, K. A.; Hou, X.; Lee, S. K.; Kim, H. O. Structure-activity relationships of truncated adenosine derivatives as highly potent and selective human A3 adenosine receptor antagonists Bioorg. Med. Chem. 2009, 17, 3733-3738 10.1016/j.bmc.2009.03.034
212. Rocha-Sousa, A.; Rodrigues-Araújo, J.; Gouveia, P.; Barbosa-Breda, J.; Azevedo-Pinto, S.; Pereira-Silva, P.; Leite-Moreira, A. New therapeutic targets for intraocular pressure lowering Int. Sch. Res. Notices 2013, 2013, 261386 10.1155/2013/261386
213. Wentz, S. M.; Kim, N. J.; Wang, J.; Amireskandari, A.; Siesky, B.; Harris, A. Novel therapies for open-angle glaucoma F1000Prime Rep. 2014, 6, 102 10.12703/P6-102
214. Wang, H.; Wang, R.; Thrimawithana, T.; Little, P. J.; Xu, J.; Feng, Z.-P.; Zheng, W. The nerve growth factor signaling and its potential as therapeutic target for glaucoma BioMed Res. Int. 2014, 2014, 759473 10.1155/2014/759473
215. Aloe, L.; Rocco, M. L.; Bianchi, P.; Manni, L. Nerve growth factor: from the early discoveries to the potential clinical use J. Transl. Med. 2012, 10, 239-239 10.1186/1479-5876-10-239
216. Kaplan, D. R.; Miller, F. D. Signal transduction by the neutrophin receptors Curr. Opin. Cell Biol. 1997, 9, 213-221 10.1016/S0955-0674(97)80065-8
217. Roberti, G.; Mantelli, F.; Macchi, I.; Massaro-Giordano, M.; Centofanti, M. Nerve growth factor modulation of retinal ganglion cell physiology J. Cell. Physiol. 2014, 229, 1130-1133 10.1002/jcp.24573
218. Carmignoto, G.; Maffei, L.; Candeo, P.; Canella, R.; Comelli, C. Effect of NGF on the survival of rat retinal ganglion cells following optic nerve section J. Neurosci. 1989, 9, 1263-1272
219. Sivilia, S.; Giuliani, A.; Fernández, M.; Turba, M. E.; Forni, M.; Massella, A.; De Sordi, N.; Giardino, L.; Calzà, L. Intravitreal NGF administration counteracts retina degeneration after permanent carotid artery occlusion in rat BMC Neurosci. 2009, 10, 52 10.1186/1471-2202-10-52
220. Lambiase, A.; Centofanti, M.; Micera, A.; Manni, G. L.; Mattei, E.; De Gregorio, A.; de Feo, G.; Bucci, M. G.; Aloe, L. Nerve growth factor (NGF) reduces and NGF antibody exacerbates retinal damage induced in rabbit by experimental ocular hypertension Graefe's Arch. Clin. Exp. Ophthalmol. 1997, 235, 780-785 10.1007/BF02332863
221. Lambiase, A.; Aloe, L.; Centofanti, M.; Parisi, V.; Mantelli, F.; Colafrancesco, V.; Manni, G. L.; Bucci, M. G.; Bonini, S.; Levi-Montalcini, R. Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: implications for glaucoma Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 13469-13474 10.1073/pnas.0906678106
222. Ferrari, M. P.; Mantelli, F.; Sacchetti, M.; Antonangeli, M. I.; Cattani, F.; D'Anniballe, G.; Sinigaglia, F.; Ruffini, P. A.; Lambiase, A. Safety and pharmacokinetics of escalating doses of human recombinant nerve growth factor eye drops in a double-masked, randomized clinical trial BioDrugs 2014, 28, 275-283 10.1007/s40259-013-0079-5
223. Nagase, H.; Woessner, J. F. Matrix metalloproteinases J. Biol. Chem. 1999, 274, 21491-21494 10.1074/jbc.274.31.21491
224. De Groef, L.; Van Hove, I.; Dekeyster, E.; Stalmans, I.; Moons, L. MMPs in the trabecular meshwork: promising targets for future glaucoma therapies? Invest. Ophthalmol. Visual Sci. 2013, 54, 7756-7763 10.1167/iovs.13-13088
225. Spiga, M.-G.; Borrás, T. Development of a gene therapy virus with a glucocorticoid-inducible MMP1 for the treatment of steroid glaucoma Invest. Ophthalmol. Visual Sci. 2010, 51, 3029-3041 10.1167/iovs.09-4918
226. Gerometta, R.; Spiga, M.-G.; Borrás, T.; Candia, O. A. Treatment of sheep steroid-induced ocular hypertension with a glucocorticoid-inducible MMP1 gene therapy virus Invest. Ophthalmol. Visual Sci. 2010, 51, 3042-3048 10.1167/iovs.09-4920
227. Rosenberg, G. A. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases Lancet Neurol. 2009, 8, 205-216 10.1016/S1474-4422(09)70016-X
228. Yong, V. W. Metalloproteinases: mediators of pathology and regeneration in the CNS Nat. Rev. Neurosci. 2005, 6, 931-944 10.1038/nrn1807
229. Chintala, S. K.; Zhang, X.; Austin, J. S.; Fini, M. E. Deficiency in matrix metalloproteinase gelatinase B (MMP-9) protects against retinal ganglion cell death after optic nerve ligation J. Biol. Chem. 2002, 277, 47461-47468 10.1074/jbc.M204824200
230. Fingert, J. H.; Heon, E.; Liebmann, J. M.; Yamamoto, T.; Craig, J. E.; Rait, J.; Kawase, K.; Hoh, S. T.; Buys, Y. M.; Dickinson, J.; Hockey, R. R.; Williams-Lyn, D.; Trope, G.; Kitazawa, Y.; Ritch, R.; Mackey, D. A.; Alward, W. L.; Sheffield, V. C.; Stone, E. M. Analysis of myocilin mutations in 1703 glaucoma patients from five different populations Hum. Mol. Genet. 1999, 8, 899-905 10.1093/hmg/8.5.899
231. Donegan, R. K.; Hill, S. E.; Freeman, D. M.; Nguyen, E.; Orwig, S. D.; Turnage, K. C.; Lieberman, R. L. Structural basis for misfolding in myocilin-associated glaucoma Hum. Mol. Genet. 2015, 24, 2111-2124 10.1093/hmg/ddu730
232. Lutjen-Drecoll, E.; May, C. A.; Polansky, J. R.; Johnson, D. H.; Bloemendal, H.; Nguyen, T. D. Localization of the stress proteins alpha B-crystallin and trabecular meshwork inducible glucocorticoid response protein in normal and glaucomatous trabecular meshwork Invest. Ophthalmol. Visual Sci. 1998, 39, 517-525
233. Takahashi, H.; Noda, S.; Mashima, Y.; Kubota, R.; Ohtake, Y.; Tanino, T.; Kudoh, J.; Minoshima, S.; Oguchi, Y.; Shimizu, N. The myocilin (MYOC) gene expression in the human trabecular meshwork Curr. Eye Res. 2000, 20, 81-84 10.1076/0271-3683(200002)2021-DFT081
234. Joe, M. K.; Kwon, H. S.; Cojocaru, R.; Tomarev, S. I. Myocilin regulates cell proliferation and survival J. Biol. Chem. 2014, 289, 10155-10167 10.1074/jbc.M113.547091
235. Koch, M. A.; Rosenhammer, B.; Koschade, S. E.; Braunger, B. M.; Volz, C.; Jägle, H.; Tamm, E. R. Myocilin modulates programmed cell death during retinal development Exp. Eye Res. 2014, 125, 41-52 10.1016/j.exer.2014.04.016
236. Buller, C.; Johnson, D. H.; Tschumper, R. C. Human trabecular meshwork phagocytosis. Observations in an organ culture system Invest. Ophthalmol. Visual Sci. 1990, 31, 2156-2163
237. Burns, J. N.; Turnage, K. C.; Walker, C. A.; Lieberman, R. L. The stability of myocilin olfactomedin domain variants provides new insight into glaucoma as a protein misfolding disorder Biochemistry 2011, 50, 5824-5833 10.1021/bi200231x
238. Orwig, S. D.; Perry, C. W.; Kim, L. Y.; Turnage, K. C.; Zhang, R.; Vollrath, D.; Schmidt-Krey, I.; Lieberman, R. L. Amyloid fibril formation by the glaucoma-associated olfactomedin domain of myocilin J. Mol. Biol. 2012, 421, 242-255 10.1016/j.jmb.2011.12.016
239. Hill, S. E.; Donegan, R. K.; Lieberman, R. L. The glaucoma-associated olfactomedin domain of myocilin forms polymorphic fibrils that are constrained by partial unfolding and peptide sequence J. Mol. Biol. 2014, 426, 921-935 10.1016/j.jmb.2013.12.002
240. Lam, D. S.; Leung, Y. F.; Chua, J. K.; Baum, L.; Fan, D. S.; Choy, K. W.; Pang, C. P. Truncations in the TIGR gene in individuals with and without primary open-angle glaucoma Invest. Ophthalmol. Visual Sci. 2000, 41, 1386-1391
241. Kim, B. S.; Savinova, O. V.; Reedy, M. V.; Martin, J.; Lun, Y.; Gan, L.; Smith, R. S.; Tomarev, S. I.; John, S. W.; Johnson, R. L. Targeted disruption of the myocilin gene (myoc) suggests that human glaucoma-causing mutations are gain of function Mol. Cell. Biol. 2001, 21, 7707-7713 10.1128/MCB.21.22.7707-7713.2001
242. Vollrath, D.; Liu, Y. Temperature sensitive secretion of mutant myocilins Exp. Eye Res. 2006, 82, 1030-1036 10.1016/j.exer.2005.10.007
243. Gobeil, S.; Letartre, L.; Raymond, V. Functional analysis of the glaucoma-causing TIGR/myocilin protein: integrity of amino-terminal coiled-coil regions and olfactomedin homology domain is essential for extracellular adhesion and secretion Exp. Eye Res. 2006, 82, 1017-1029 10.1016/j.exer.2005.11.002
244. Liu, Y.; Vollrath, D. Reversal of mutant myocilin non-secretion and cell killing: implications for glaucoma Hum. Mol. Genet. 2004, 13, 1193-1204 10.1093/hmg/ddh128
245. Jia, L.-Y.; Gong, B.; Pang, C.-P.; Huang, Y.; Lam, D. S.-C.; Wang, N.; Yam, G. H.-F. Correction of the disease phenotype of myocilin-causing glaucoma by a natural osmolyte Invest. Ophthalmol. Visual Sci. 2009, 50, 3743-3749 10.1167/iovs.08-3151
246. Yam, G. H.-F.; Gaplovska-Kysela, K.; Zuber, C.; Roth, J. Sodium 4-phenylbutyrate acts as a chemical chaperone on misfolded myocilin to rescue cells from endoplasmic reticulum stress and apoptosis Invest. Ophthalmol. Visual Sci. 2007, 48, 1683-1690 10.1167/iovs.06-0943
247. Balch, W. E.; Morimoto, R. I.; Dillin, A.; Kelly, J. W. Adapting proteostasis for disease intervention Science 2008, 319, 916-919 10.1126/science.1141448
248. Burns, J. N.; Orwig, S. D.; Harris, J. L.; Watkins, J. D.; Vollrath, D.; Lieberman, R. L. Rescue of glaucoma-causing mutant myocilin thermal stability by chemical chaperones ACS Chem. Biol. 2010, 5, 477-487 10.1021/cb900282e
249. Orwig, S. D.; Chi, P. V.; Du, Y.; Hill, S. E.; Cavitt, M. A.; Suntharalingam, A.; Turnage, K. C.; Dickey, C. A.; France, S.; Fu, H.; Lieberman, R. L. Ligands for glaucoma-associated myocilin discovered by a generic binding assay ACS Chem. Biol. 2014, 9, 517-525 10.1021/cb4007776
250. Guerriero, C. J.; Brodsky, J. L. The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology Physiol. Rev. 2012, 92, 537-576 10.1152/physrev.00027.2011
251. Zode, G. S.; Bugge, K. E.; Mohan, K.; Grozdanic, S. D.; Peters, J. C.; Koehn, D. R.; Anderson, M. G.; Kardon, R. H.; Stone, E. M.; Sheffield, V. C. Topical ocular sodium 4-phenylbutyrate rescues glaucoma in a myocilin mouse model of primary open-angle glaucoma Invest. Ophthalmol. Visual Sci. 2012, 53, 1557-1565 10.1167/iovs.11-8837
252. Rubenstein, R. C.; Zeitlin, P. L. Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of ΔF508-CFTR Am. J. Physiol.: Cell Physiol. 2000, 278, C259-C267
253. Gong, B.; Zhang, L.-Y.; Lam, D. S.-C.; Pang, C.-P.; Yam, G. H.-F. Sodium 4-phenylbutyrate ameliorates the effects of cataract-causing mutant gammaD-crystallin in cultured cells Mol. Vision 2010, 16, 997-1003
254. Basseri, S.; Lhoták, Š.; Sharma, A. M.; Austin, R. C. The chemical chaperone 4-phenylbutyrate inhibits adipogenesis by modulating the unfolded protein response J. Lipid Res. 2009, 50, 2486-2501 10.1194/jlr.M900216-JLR200
255. Suntharalingam, A.; Abisambra, J. F.; O'Leary, J. C.; Koren, J.; Zhang, B.; Joe, M. K.; Blair, L. J.; Hill, S. E.; Jinwal, U. K.; Cockman, M. Glucose-regulated protein 94 triage of mutant myocilin through endoplasmic reticulum-associated degradation subverts a more efficient autophagic clearance mechanism J. Biol. Chem. 2012, 287, 40661-40669 10.1074/jbc.M112.384800
256. Stothert, A. R.; Suntharalingam, A.; Huard, D. J.; Fontaine, S. N.; Crowley, V. M.; Mishra, S.; Blagg, B. S.; Lieberman, R. L.; Dickey, C. A. Exploiting the interaction between Grp94 and aggregated myocilin to treat glaucoma Hum. Mol. Genet. 2014, 23, 6470-6480 10.1093/hmg/ddu367
257. Zhang, X.; Zhang, L.; Wang, S.; Wu, D.; Yang, W. Decreased functional expression of Grp78 and Grp94 inhibits proliferation and attenuates apoptosis in a human gastric cancer cell line in vitro Oncol. Lett. 2015, 9, 1181-1186 10.3892/ol.2014.2831
258. Wang, Q.; He, Z.; Zhang, J.; Wang, Y.; Wang, T.; Tong, S.; Wang, L.; Wang, S.; Chen, Y. Overexpression of endoplasmic reticulum molecular chaperone GRP94 and GRP78 in human lung cancer tissues and its significance Cancer Detect. Prev. 2005, 29, 544-551 10.1016/j.cdp.2005.09.010
259. Reddy, R. K.; Lu, J.; Lee, A. S. The endoplasmic reticulum chaperone glycoprotein GRP94 with Ca2+-binding and antiapoptotic properties is a novel proteolytic target of calpain during etoposide-induced apoptosis J. Biol. Chem. 1999, 274, 28476-28483 10.1074/jbc.274.40.28476
260. Bando, Y.; Katayama, T.; Aleshin, A.; Manabe, T.; Tohyama, M. GRP94 reduces cell death in SH-SY5Y cells perturbated calcium homeostasis Apoptosis 2004, 9, 501-508 10.1023/B:APPT.0000031446.95532.ad
261. Borrás, T. Advances in glaucoma treatment and management: gene therapy Invest. Ophthalmol. Visual Sci. 2012, 53, 2506-2510 10.1167/iovs.12-9483o
262. Martínez, T.; González, M. V.; Roehl, I.; Wright, N.; Pañeda, C.; Jiménez, A. I. In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma Mol. Ther. 2014, 22, 81-91 10.1038/mt.2013.216
263. Simonato, M.; Bennett, J.; Boulis, N. M.; Castro, M. G.; Fink, D. J.; Goins, W. F.; Gray, S. J.; Lowenstein, P. R.; Vandenberghe, L. H.; Wilson, T. J. Progress in gene therapy for neurological disorders Nat. Rev. Neurol. 2013, 9, 277-291 10.1038/nrneurol.2013.56
264. Patel, A.; Cholkar, K.; Agrahari, V.; Mitra, A. K. Ocular drug delivery systems: An overview World J. Pharmacol. 2013, 2, 47-64 10.5497/wjp.v2.i2.47
265. Guzman-Aranguez, A.; Colligris, B.; Pintor, J. Contact lenses: promising devices for ocular drug delivery J. Ocul. Pharmacol. Ther. 2013, 29, 189-199 10.1089/jop.2012.0212
266. Molokhia, S. A.; Thomas, S. C.; Garff, K. J.; Mandell, K. J.; Wirostko, B. M. Anterior eye segment drug delivery systems: current treatments and future challenges J. Ocul. Pharmacol. Ther. 2013, 29, 92-105 10.1089/jop.2012.0241
267. Achouri, D.; Alhanout, K.; Piccerelle, P.; Andrieu, V. Recent advances in ocular drug delivery Drug Dev. Ind. Pharm. 2013, 39, 1599-1617 10.3109/03639045.2012.736515
268. Wehrman, T.; He, X.; Raab, B.; Dukipatti, A.; Blau, H.; Garcia, K. C. Structural and mechanistic insights into nerve growth factor interactions with the TrkA and p75 receptors Neuron 2007, 53, 25-38 10.1016/j.neuron.2006.09.034
269. Morgunova, E.; Tuuttila, A.; Bergmann, U.; Isupov, M.; Lindqvist, Y.; Schneider, G.; Tryggvason, K. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed Science 1999, 284, 1667-1670 10.1126/science.284.5420.1667
270. Dollins, D. E.; Warren, J. J.; Immormino, R. M.; Gewirth, D. T. Structures of GRP94-nucleotide complexes reveal mechanistic differences between the hsp90 chaperones Mol. Cell 2007, 28, 41-56 10.1016/j.molcel.2007.08.024
271. Immormino, R. M.; Metzger, L. E., IV; Reardon, P. N.; Dollins, D. E.; Blagg, B. S. J.; Gewirth, D. T. Different poses for ligand and chaperone in inhibitor-bound Hsp90 and GRP94: implications for paralog-specific drug design J. Mol. Biol. 2009, 388, 1033-1042 10.1016/j.jmb.2009.03.071
272. Garnock-Jones, K. P. Ripasudil: first global approval Drugs 2014, 74, 2211-2215 10.1007/s40265-014-0333-2
273. Fredholm, B. B.; Irenius, E.; Kull, B.; Schulte, G. Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells1 Biochem. Pharmacol. 2001, 61, 443-448 10.1016/S0006-2952(00)00570-0
274. Jacobson, K. A.; Gao, Z.-G. Adenosine receptors as therapeutic targets Nat. Rev. Drug Discovery 2006, 5, 247-264 10.1038/nrd1983
275. Cunha, R. A.; Constantino, M.; Sebastião, A.; Johansson, B.; Fredholm, B. B. Evidence for high-affinity binding sites for the adenosine A2A receptor agonist [3H] CGS 21680 in the rat hippocampus and cerebral cortex that are different from striatal A2A receptors Naunyn-Schmiedeberg's Arch. Pharmacol. 1996, 353, 261-271 10.1007/BF00168627
276. Mathoît, R.; Wenden, E.; Soudijn, W.; IJzerman, A.; Danhof, M. Deoxyribose analogues of N6-cyclopentyladenosine (CPA): partial agonists at the adenosine A1 receptor in vivo Br. J. Pharmacol. 1995, 116, 1957-1964 10.1111/j.1476-5381.1995.tb16398.x
277. Day, Y.-J.; Li, Y.; Rieger, J. M.; Ramos, S. I.; Okusa, M. D.; Linden, J. A2A adenosine receptors on bone marrow-derived cells protect liver from ischemia-reperfusion injury J. Immunol. 2005, 174, 5040-5046 10.4049/jimmunol.174.8.5040
278. Jacobson, K. A.; Park, K.-S.; Jiang, J.-L.; Kim, Y.-C.; Olah, M. E.; Stiles, G. L.; Ji, X.-D. Pharmacological characterization of novel A(3) adenosine receptor-selective antagonists Neuropharmacology 1997, 36, 1157-1165 10.1016/S0028-3908(97)00104-4
279. Jeong, L. S.; Choe, S. A.; Gunaga, P.; Kim, H. O.; Lee, H. W.; Lee, S. K.; Tosh, D. K.; Patel, A.; Palaniappan, K. K.; Gao, Z.-G.; Jacobson, K. A.; Moon, H. R. Discovery of a new nucleoside template for human A3 adenosine receptor ligands: d-4'-thioadenosine derivatives without 4'-hydroxymethyl group as highly potent and selective antagonists J. Med. Chem. 2007, 50, 3159-3162 10.1021/jm070259t
280. Comes, N.; Buie, L. K.; Borrás, T. Evidence for a role of angiopoietin-like 7 (ANGPTL7) in extracellular matrix formation of the human trabecular meshwork: implications for glaucoma Genes Cells 2011, 16, 243-259 10.1111/j.1365-2443.2010.01483.x
281. Goel, M.; Sienkiewicz, A. E.; Picciani, R.; Wang, J.; Lee, R. K.; Bhattacharya, S. K. Cochlin, intraocular pressure regulation and mechanosensing PLoS One 2012, 7, e34309 10.1371/journal.pone.0034309
282. Iyer, P.; Maddala, R.; Pattabiraman, P. P.; Rao, P. V. Connective tissue growth factor-mediated upregulation of neuromedin: expression in trabecular meshwork cells and its role in homeostasis of aqueous humor outflow Invest. Ophthalmol. Visual Sci. 2012, 53, 4952-4962 10.1167/iovs.12-9681
283. Junglas, B.; Kuespert, S.; Seleem, A. A.; Struller, T.; Ullmann, S.; Bösl, M.; Bosserhoff, A.; Köstler, J.; Wagner, R.; Tamm, E. R.; Fuchshofer, R. Connective tissue growth factor causes glaucoma by modifying the actin cytoskeleton of the trabecular meshwork Am. J. Pathol. 2012, 180, 2386-2403 10.1016/j.ajpath.2012.02.030
284. Rosenthal, R.; Fromm, M. Endothelin antagonism as an active principle for glaucoma therapy Br. J. Pharmacol. 2011, 162, 806-816 10.1111/j.1476-5381.2010.01103.x
285. Rocha-Sousa, A.; Pereira-Silva, P.; Tavares-Silva, M.; Azevedo-Pinto, S.; Rodrigues-Araújo, J.; Pinho, S.; Avelino, A.; Falcão-Reis, F.; Leite-Moreira, A. Identification of the ghrelin-GHSR 1 system and its influence in the modulation of induced ocular hypertension in rabbit and rat eyes Peptides 2014, 57, 59-66 10.1016/j.peptides.2014.04.013
286. Rasmussen, C. A.; Kaufman, P. L.; Ritch, R.; Haque, R.; Brazzell, R. K.; Vittitow, J. L. Latrunculin B reduces intraocular pressure in human ocular hypertension and primary open-angle glaucoma Transl. Vis. Sci. Technol. 2014, 3, 1 10.1167/tvst.3.5.1
287. Pintor, J.; Peláez, T.; Hoyle, C. H.; Peral, A. Ocular hypotensive effects of melatonin receptor agonists in the rabbit: further evidence for an MT3 receptor Br. J. Pharmacol. 2003, 138, 831-836 10.1038/sj.bjp.0705118
288. Wiederholt, M.; Sturm, A.; Lepple-Wienhues, A. Relaxation of trabecular meshwork and ciliary muscle by release of nitric oxide Invest. Ophthalmol. Visual Sci. 1994, 35, 2515-2520
289. Kaufman, P. L.; Rasmussen, C. A. Advances in glaucoma treatment and management: outflow drugs Invest. Ophthalmol. Visual Sci. 2012, 53, 2495-2500 10.1167/iovs.12-9483m
290. Fuchshofer, R.; Tamm, E. R. The role of TGF-β in the pathogenesis of primary open-angle glaucoma Cell Tissue Res. 2012, 347, 279-290 10.1007/s00441-011-1274-7